Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$201.50
+2.0%
$195.49
$123.41
$211.96
$35.94B1.911.53 million shs1.87 million shs
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$438.18
+1.3%
$404.59
$289.36
$442.30
$142.20B1.42.60 million shs2.41 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$125.00
-0.5%
$105.05
$62.55
$142.79
$47.86B1.573.45 million shs4.51 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
+1.96%-3.01%-0.85%+34.14%+56.47%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
+1.32%+2.56%+5.87%+13.00%+33.36%
Moderna, Inc. stock logo
MRNA
Moderna
-0.47%+15.77%+23.51%+28.21%-3.95%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
4.246 of 5 stars
2.43.03.30.02.72.52.5
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
4.709 of 5 stars
2.44.02.53.03.12.52.5
Moderna, Inc. stock logo
MRNA
Moderna
3.4265 of 5 stars
2.12.00.04.61.93.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
2.74
Moderate Buy$204.371.42% Upside
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
2.75
Moderate Buy$437.04-0.26% Downside
Moderna, Inc. stock logo
MRNA
Moderna
2.25
Hold$129.553.64% Upside

Current Analyst Ratings

Latest FANG, GS, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/3/2024
Moderna, Inc. stock logo
MRNA
Moderna
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$91.00 ➝ $106.00
5/3/2024
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$125.00 ➝ $135.00
5/3/2024
Moderna, Inc. stock logo
MRNA
Moderna
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$142.00 ➝ $163.00
5/2/2024
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$227.00 ➝ $224.00
5/2/2024
Moderna, Inc. stock logo
MRNA
Moderna
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/30/2024
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$479.00 ➝ $517.00
4/23/2024
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$224.00 ➝ $229.00
4/22/2024
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$248.00 ➝ $250.00
4/22/2024
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$210.00 ➝ $225.00
4/22/2024
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Susquehanna
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetPositive ➝ Positive$212.00 ➝ $245.00
4/19/2024
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$227.00 ➝ $247.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$8.41B4.27$28.54 per share7.06$101.04 per share1.99
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$108.42B1.31$41.53 per share10.55$363.61 per share1.21
Moderna, Inc. stock logo
MRNA
Moderna
$5.08B9.42N/AN/A$33.47 per share3.73

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$3.14B$17.7411.369.41N/A36.71%19.36%11.62%7/29/2024 (Estimated)
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$8.52B$25.6117.1111.181.368.17%8.65%0.58%7/17/2024 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$4.71B-$15.67N/AN/AN/A-115.82%-20.10%-15.00%8/1/2024 (Estimated)

Latest FANG, GS, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024Q1 2024
Moderna, Inc. stock logo
MRNA
Moderna
-$3.59-$3.07+$0.52-$3.07$93.26 million$167.00 million    
4/30/2024Q1 24
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$4.29$4.50+$0.21$4.72$2.10 billion$2.23 billion    
4/15/2024Q1 2024
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$8.54$11.58+$3.04$11.58$12.94 billion$14.21 billion    
2/22/2024Q4 2023
Moderna, Inc. stock logo
MRNA
Moderna
-$0.78$0.55+$1.33$0.55$2.53 billion$2.80 billion    
2/20/2024Q4 23
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$4.61$4.74+$0.13$4.14$2.16 billion$2.23 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
$3.601.79%+29.80%20.29%6 Years
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$11.002.51%+28.06%42.95%3 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest FANG, GS, and MRNA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/11/2024
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Quarterly$2.752.77%5/30/20245/30/20246/27/2024
4/30/2024
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
quarterly$0.901.79%5/14/20245/15/20245/22/2024
2/15/2024
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
Quarterly$3.086.85%3/4/20243/5/20243/12/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
0.37
0.92
0.74
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
1.98
1.12
0.76
Moderna, Inc. stock logo
MRNA
Moderna
0.04
4.03
3.36

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
90.01%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
71.21%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
0.43%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
0.54%
Moderna, Inc. stock logo
MRNA
Moderna
15.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Diamondback Energy, Inc. stock logo
FANG
Diamondback Energy
1,023178.34 million177.57 millionOptionable
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
45,300324.53 million322.78 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,600382.88 million322.77 millionOptionable

FANG, GS, and MRNA Headlines

SourceHeadline
Analysts Are Updating Their Moderna, Inc. (NASDAQ:MRNA) Estimates After Its First-Quarter ResultsAnalysts Are Updating Their Moderna, Inc. (NASDAQ:MRNA) Estimates After Its First-Quarter Results
finance.yahoo.com - May 4 at 5:06 PM
Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call TranscriptModerna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript
finance.yahoo.com - May 4 at 5:06 PM
Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan Sells 15,000 SharesModerna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan Sells 15,000 Shares
insidertrades.com - May 4 at 7:32 AM
Moderna (NASDAQ:MRNA) Announces Quarterly  Earnings ResultsModerna (NASDAQ:MRNA) Announces Quarterly Earnings Results
marketbeat.com - May 3 at 11:54 PM
Canaccord Genuity Group Increases Moderna (NASDAQ:MRNA) Price Target to $106.00Canaccord Genuity Group Increases Moderna (NASDAQ:MRNA) Price Target to $106.00
marketbeat.com - May 3 at 10:16 PM
Moderna, Inc. (NASDAQ:MRNA) Director Sells $1,663,800.00 in StockModerna, Inc. (NASDAQ:MRNA) Director Sells $1,663,800.00 in Stock
marketbeat.com - May 3 at 8:16 PM
Modernas Loss in Q1 Was Less Than ExpectedModerna's Loss in Q1 Was Less Than Expected
fool.com - May 3 at 7:20 PM
Navigating 6 Analyst Ratings For ModernaNavigating 6 Analyst Ratings For Moderna
markets.businessinsider.com - May 3 at 7:20 PM
Shhh! 3 Secret Pharma Stocks Flying Below Wall Streets RadarShhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar
investorplace.com - May 3 at 6:15 AM
MRNA Earnings: Moderna Reports Mixed Results in Q1MRNA Earnings: Moderna Reports Mixed Results in Q1
msn.com - May 3 at 12:26 AM
Moderna’s stock surges after better-than-expected quarterly resultsModerna’s stock surges after better-than-expected quarterly results
msn.com - May 3 at 12:26 AM
Why Moderna Stock Blasted 13% Higher TodayWhy Moderna Stock Blasted 13% Higher Today
fool.com - May 2 at 6:36 PM
Moderna (NASDAQ:MRNA) Stock Price Up 9.4%Moderna (NASDAQ:MRNA) Stock Price Up 9.4%
marketbeat.com - May 2 at 5:44 PM
Moderna (NASDAQ:MRNA) Rating Reiterated by Needham & Company LLCModerna (NASDAQ:MRNA) Rating Reiterated by Needham & Company LLC
marketbeat.com - May 2 at 2:39 PM
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after reviewModerna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
fiercebiotech.com - May 2 at 2:25 PM
Moderna gears up for potential RSV vaccine launch this fall after better-than-expected first quarterModerna gears up for potential RSV vaccine launch this fall after better-than-expected first quarter
fiercepharma.com - May 2 at 2:25 PM
Moderna (MRNA) Q1 2024 Earnings Call TranscriptModerna (MRNA) Q1 2024 Earnings Call Transcript
msn.com - May 2 at 2:25 PM
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock SoarsModerna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars
msn.com - May 2 at 2:25 PM
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/YModerna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
zacks.com - May 2 at 12:16 PM
MRNA Stock Earnings: Moderna Beats EPS, Beats Revenue for Q1 2024MRNA Stock Earnings: Moderna Beats EPS, Beats Revenue for Q1 2024
investorplace.com - May 2 at 12:03 PM
Moderna, Inc. 2024 Q1 - Results - Earnings Call PresentationModerna, Inc. 2024 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 2 at 11:19 AM
2 Biotech Stocks To Watch Today Amid Earnings2 Biotech Stocks To Watch Today Amid Earnings
stockmarket.com - May 2 at 10:18 AM
Moderna: Q1 Earnings SnapshotModerna: Q1 Earnings Snapshot
thehour.com - May 2 at 9:25 AM
Moderna Walks Away from Potential $3B Gene Editing Deal with MetagenomiModerna Walks Away from Potential $3B Gene Editing Deal with Metagenomi
biospace.com - May 2 at 9:25 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Diamondback Energy logo

Diamondback Energy

NASDAQ:FANG
Diamondback Energy, Inc., an independent oil and natural gas company, acquires, develops, explores, and exploits unconventional, onshore oil and natural gas reserves in the Permian Basin in West Texas. It focuses on the development of the Spraberry and Wolfcamp formations of the Midland basin; and the Wolfcamp and Bone Spring formations of the Delaware basin, which are part of the Permian Basin in West Texas and New Mexico. The company also owns and operates midstream infrastructure assets, in the Midland and Delaware Basins of the Permian Basin. Diamondback Energy, Inc. was founded in 2007 and is headquartered in Midland, Texas.
The Goldman Sachs Group logo

The Goldman Sachs Group

NYSE:GS
The Goldman Sachs Group, Inc., a financial institution, provides a range of financial services for corporations, financial institutions, governments, and individuals worldwide. It operates through Global Banking & Markets, Asset & Wealth Management, and Platform Solutions segments. The Global Banking & Markets segment provides financial advisory services, including strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, and spin-offs; and relationship lending, and acquisition financing, as well as secured lending, through structured credit and asset-backed lending and involved in financing under securities to resale agreements. This segment also offers client execution activities for cash and derivative instruments; credit and interest rate products; and provision of mortgages, currencies, commodities, and equities related products, as well as underwriting services. The Asset & Wealth Management segment manages assets across various classes, including equity, fixed income, hedge funds, credit funds, private equity, real estate, currencies, and commodities; and provides customized investment advisory solutions, wealth advisory services, personalized financial planning, and private banking services, as well as invests in corporate equity, credit, real estate, and infrastructure assets. The Platform Solutions segment offers credit cards and point-of-sale financing for purchase of goods or services. This segment also provides cash management services, such as deposit-taking and payment solutions for corporate and institutional clients. The Goldman Sachs Group, Inc. was founded in 1869 and is headquartered in New York, New York.
Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.